BiotechTube

Remicade

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing

Trial Timeline

Aug 1, 2005 → Aug 1, 2005

NCT ID
NCT00778869

About Remicade

Remicade is a approved stage product being developed by Merck for Spondylitis, Ankylosing. The current trial status is completed. This product is registered under clinical trial identifier NCT00778869. Target conditions include Spondylitis, Ankylosing.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (3)

NCT IDPhaseStatus
NCT00778869ApprovedCompleted
NCT00779935ApprovedCompleted
NCT00705614Pre-clinicalCompleted

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
33
InfliximabCelltrionPhase 1
33
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
52
adalimumabEisaiPhase 3
77
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
77
Tramadol /acetaminophen + DiclofenacJohnson & JohnsonApproved
85
Golimumab + PlaceboJohnson & JohnsonPhase 3
77
GolimumabJohnson & JohnsonApproved
85
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
65
placebo for risankizumab + risankizumabAbbViePhase 2
52
Upadacitinib + PlaceboAbbViePhase 2
52
AdalimumabAbbViePre-clinical
23
infliximab + PlaceboMerckPhase 3
77
InfliximabMerckApproved
85
Infliximab + Placebo + NaproxenMerckPhase 3
77
InfliximabMerckPre-clinical
23
GolimumabMerckApproved
85
RemicadeMerckApproved
85
InfliximabMerckApproved
85
InfliximabMerckApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85